ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1

Future Oncology, Ahead of Print.

Source: Future Oncology - April 5, 2020 Category: Cancer & Oncology Authors: Grzegorz S Nowakowski Jun Zhu Qingyuan Zhang Joshua Brody Xiuhua Sun Joseph Maly Yuqin Song Syed Rizvi Yongping Song Frederick Lansigan Hongmei Jing Junning Cao Jennifer K Lue Wen Luo Lei Zhang Ling Li Isabel Han Joan Sun Manoj Jivani Young Liu Thomas Hei Source Type: research